Which is why OSE Immunotherapeutics is developing a vaccine that aims to be pan-coronavirus. The formulation for CoVepiT, which focuses on inducing a lasting T cell immune response, is made up of 11 total viral targets. This way, even if one changes, there are still 10 other potentially valid targets.